Peptide Cycling Protocols

Introduction

Peptide users borrowed cycling from steroid and SARM users. They pause to let natural testosterone recover; peptide users expect the response to fade. Most schedules below come from vendors or users, not trials.

Cycling Fundamentals

Purpose of Cycling

Goal	Mechanism	Evidence
Receptor sensitivity	Limit downregulation	Partial (one hexarelin study)
Health monitoring	Assessment periods	Untested
Cost management	Structured use	Practical

In a 1998 study of 12 older adults, the growth hormone response to twice-daily hexarelin fell about 45% over 16 weeks, then recovered after a 4-week break. In a 2-year MK-677 trial, IGF-1 stayed raised.

Basic Cycle Structure

Phase	Reported duration	Purpose
On-cycle	8-16 weeks	Active use
Off-cycle	4-8 weeks	Rest

Common Protocols

Growth Hormone Secretagogues

Protocol	Structure (community guides)	Notes
Standard	12 weeks on, 4 weeks off	Most common
Extended	16 weeks on, 6 weeks off	Some users
5-on-2-off	5 days on, 2 off weekly	Mod GRF 1-29 with ipamorelin

Recovery Peptides (BPC-157, TB-500)

Protocol	Vendor-reported duration	Purpose
Injury-specific	4-12 weeks (BPC-157)	Targeted healing
Loading	TB-500 2-2.5 mg twice weekly, 4-6 weeks	Acute injury
Maintenance	Monthly TB-500 after loading	Ongoing use

Users report 250-500 mcg/day of BPC-157 and 2-5 mg of TB-500 twice weekly; no human study has tested either.

Stacking Strategies

Common Combinations

Stack	Purpose	Considerations
GHRP + GHRH analog	GH release	No controlled trial (stack comparison)
BPC-157 + TB-500	Recovery	Untested together
Ipamorelin + CJC-1295	GH support	Usually no-DAC form, 100-300 mcg each (user reports)

Timing Considerations

Factor	Common practice	Rationale (untested)
GHRP timing	Empty stomach	Ghrelin mimetic effect
Sleep enhancement	Before bed	Overnight GH pulse
Stacking intervals	15-30 min apart or together	Habit

Monitoring During Cycles

Key Markers

Marker	Often-cited frequency	Purpose
IGF-1 levels	Monthly	Efficacy assessment
Fasting glucose	Monthly	MK-677 raised it in trials
Blood pressure	Weekly	Cardiovascular

SARM users also track testosterone: in a 21-day trial, LGD-4033 (0.1-1 mg daily) lowered it, with recovery after stopping.

Adjustment Indicators

Users commonly change or end a cycle after:

Side effects emerging
Plateau in response
Blood marker changes
Goal achievement

What we still don't know

No trial has compared cycled with continuous peptide use. Steroids give a clearer reason to stop: Danish men about 2.5 years off steroids still had lower testosterone than non-users (long-term effects comparison).

Comparison table

Dimension	Peptides	SARMs	Anabolic steroids
Mechanism	Pathway-specific signaling	Androgen receptor	Androgen receptor
Why users cycle	Expected fading	Testosterone recovery	Testosterone recovery
Half-life	Hours to a week	Long (LGD-4033)	Varies by ester
Common side effects	Injection reactions, higher glucose	Lower testosterone	Lower testosterone, reduced fertility
WADA status (as of October 2026)	Most banned (anti-doping rules)	Banned (S1.2)	Banned (S1)
Evidence strength	Low	Medium	Decades of human data